AbbVie News Center

Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

Tue, 03 Nov 2026 08:00:00 -0500

– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial...

AbbVie Reports Third-Quarter 2026 Financial Results

Fri, 30 Oct 2026 07:46:00 -0400

Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an...

The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18

Wed, 28 Oct 2026 08:00:00 -0400

The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day...

Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)

Tue, 27 Oct 2026 08:30:00 -0400

Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026...

AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

Tue, 27 Oct 2026 08:00:00 -0400

– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of...

Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.

Mon, 26 Oct 2026 08:00:00 -0400

Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide. A STEM-focused workshop in San Antonio...

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Fri, 23 Oct 2026 15:33:00 -0400

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In...

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

Thu, 22 Oct 2026 09:00:00 -0400

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked...

Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence

Wed, 21 Oct 2026 08:00:00 -0400

Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM®, SKINVIVE™ and BOTOX® Cosmetic The latest HArmonyCa™ data...

AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community

Tue, 20 Oct 2026 07:55:00 -0400

Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the...